We are live on ! Find out more
ER

Enlightenment Research Portfolio holdings

AUM $45.2M
1-Year Est. Return 15.22%
This Fund
S&P 500
This Quarter Est. Return
+2.65%
1 Year Est. Return
-15.22%
3 Year Est. Return
+194.97%
5 Year Est. Return
10 Year Est. Return
AUM
$197M
AUM Growth
+$145M
Cap. Flow
+$148M
Cap. Flow %
75.44%
Top 10 Hldgs %
25.85%
Holding
307
New
213
Increased
32
Reduced
20
Closed
42

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$15.3M
2
NVDA icon
NVIDIA
NVDA
+$5.87M
3
CSCO icon
Cisco
CSCO
+$5.74M
4
BABA icon
Alibaba
BABA
+$4.18M
5
CMCSA icon
Comcast
CMCSA
+$3.23M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.93M
2
CHTR icon
Charter Communications
CHTR
+$1.53M
3
BMY icon
Bristol-Myers Squibb
BMY
+$1.23M
4
NFLX icon
Netflix
NFLX
+$1.03M
5
CVX icon
Chevron
CVX
+$936K

Sector Composition

Rank Sector Weight
1 Technology 34.53%
2 Consumer Discretionary 11.92%
3 Healthcare 11.03%
4 Communication Services 8.14%
5 Consumer Staples 7.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DPZ icon
76
Domino's
DPZ
$11.9B
$704K 0.36%
+2,600
New +$711K
KR icon
77
Kroger
KR
$36.7B
$698K 0.36%
+31,600
New +$769K
ZNGA
78
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
$693K 0.35%
112,995
+92,595
+454% +$546K
DAL icon
79
Delta Air Lines
DAL
$56.8B
$688K 0.35%
+12,493
New +$700K
CL icon
80
Colgate-Palmolive
CL
$75B
$680K 0.35%
+9,607
New +$682K
ABBV icon
81
AbbVie
ABBV
$467B
$675K 0.34%
+8,500
New +$668K
PEP icon
82
PepsiCo
PEP
$196B
$674K 0.34%
+5,200
New +$667K
CME icon
83
CME Group
CME
$95.4B
$662K 0.34%
+3,700
New +$682K
WYNN icon
84
Wynn Resorts
WYNN
$10.3B
$662K 0.34%
+5,300
New +$681K
SAP icon
85
SAP
SAP
$215B
$657K 0.33%
+4,900
New +$610K
ALXN
86
DELISTED
Alexion Pharmaceuticals
ALXN
$637K 0.32%
+5,600
New +$722K
LYB icon
87
LyondellBasell Industries
LYB
$19.6B
$636K 0.32%
+7,300
New +$623K
MRVL icon
88
Marvell Technology
MRVL
$147B
$623K 0.32%
+26,100
New +$610K
CMI icon
89
Cummins
CMI
$83.6B
$618K 0.31%
+4,100
New +$671K
LRCX icon
90
Lam Research
LRCX
$314B
$611K 0.31%
35,000
+16,000
+84% +$304K
EW icon
91
Edwards Lifesciences
EW
$49.3B
$610K 0.31%
+9,900
New +$599K
SRPT icon
92
Sarepta Therapeutics
SRPT
$1.64B
$608K 0.31%
5,200
+3,466
+200% +$421K
MRO
93
DELISTED
Marathon Oil Corporation
MRO
$603K 0.31%
+35,400
New +$547K
XOM icon
94
ExxonMobil
XOM
$651B
$602K 0.31%
8,500
-2,000
-19% -$155K
ULTA icon
95
Ulta Beauty
ULTA
$21.8B
$600K 0.31%
+1,800
New +$622K
FICO icon
96
Fair Isaac
FICO
$31.9B
$587K 0.3%
+2,100
New +$609K
NSC icon
97
Norfolk Southern
NSC
$75.7B
$575K 0.29%
+2,900
New +$575K
PSX icon
98
Phillips 66
PSX
$83B
$573K 0.29%
+6,073
New +$545K
AGN
99
DELISTED
Allergan plc
AGN
$567K 0.29%
+3,900
New +$540K
INTU icon
100
Intuit
INTU
$91.2B
$563K 0.29%
+2,300
New +$584K

Similar funds

Enlightenment Research's Q2 2019 Portfolio in Review

As of Q2 2019, Enlightenment Research held 307 positions worth $197M, up 283% from $51.4M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Enlightenment Research deployed $148M of net new capital in Q2 2019, opening 213 new positions and adding to 32 existing holdings. Its largest new stake was NVIDIA: 1,416,000 shares worth $4.79M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Walmart Inc, an estimated $755K trimmed.

  • Enlightenment Research's largest Q2 2019 buy was NVIDIA: 1,416,000 shares worth $4.79M.
  • Enlightenment Research added most to Apple in Q2 2019, an estimated $15.3M increase.
  • Enlightenment Research's biggest Q2 2019 reduction was Walmart Inc, cutting an estimated $755K.
  • Enlightenment Research fully exited Celgene Corp in Q2 2019, selling an estimated $1.93M.
  • Enlightenment Research's ten largest holdings make up 26% of its $197M portfolio in Q2 2019.
  • Enlightenment Research opened 213 new positions and closed 42 in Q2 2019.
  • Enlightenment Research's portfolio value rose 283% quarter-over-quarter to $197M.

Based on Enlightenment Research's 13F filing for Q2 2019, filed 5 Aug 2019.